Top 10 list of 2017 drug "blacklist"

[China Pharmaceutical network industry trends] the pharmaceutical industry is related to people's health, and drug quality is the foundation and lifeline of pharmaceutical production and distribution enterprises In 2017, which enterprises have been frequently listed in the "black list" of drugs issued by the State Food and Drug Administration (hereinafter referred to as CFDA)? According to the statistics of global health reporters, CFDA issued 46 drug sampling notices in 2017, including 22 notices on unqualified pieces of traditional Chinese medicine, 19 notices on unqualified drugs, and 5 notices on other sampling tests such as drug packaging materials, pharmaceutical accessories, etc According to the data statistics and analysis, the top 10 drug "black list" of CFDA in 2017 was obtained The top three companies were Sinopharm holding, Tongrentang and China Resources Pharmaceutical Group, and Bozhou Haomen Herbal Pieces Co., Ltd was also ranked third Sinopharm holding, Tongrentang and China Resources pharmaceutical ranked first in the "black list" with 18 times of listing, mainly due to the unqualified drugs and herbal pieces sold by Sinopharm Holding Co., Ltd and its local subsidiaries Although Sinopharm holdings is a non production enterprise, pharmaceutical distribution enterprises are also responsible for the evaluation, control, communication and audit of drug quality As a large pharmaceutical distribution enterprise in China, Sinopharm holdings should set an example in the control of drug quality Tongrentang is the national Chinese medicine industry, ranking second in 14 achievements Among them, the Chinese herbal pieces produced by Beijing Tongrentang (Bozhou) limited liability company have been listed on the list for 5 times, involving Eucommia ulmoides, myrrh, frankincense, alum, woodlouse worms and Polygala tenuifolia In addition, Tongrentang chain drugstores across the country have been notified 10 times as the "source of inspection products" Not only that, Tongrentang also often appears in the "black list" of the local food and drug administration, mainly due to the unqualified Chinese herbal pieces On November 7, Beijing Tongrentang Yinchuan drugstore Co., Ltd was named by Ningxia food and drug administration On October 23, Beijing Tongrentang (Bozhou) decoction pieces Co., Ltd was named by Fujian food and Drug Administration Unfortunately, Tongrentang didn't give a reasonable explanation for this despite frequent blacklisting nationwide in the past year "Black list" the third is China Resources Pharmaceutical Group, a total of eight times on the list China Resources pharmaceutical's business volume ranks second only to Sinopharm holding in China's pharmaceutical business According to the public information, China Resources pharmaceutical group includes China Resources Shuanghe Pharmaceutical Co., Ltd., China Resources Sanjiu Pharmaceutical Co., Ltd and China Resources Pharmaceutical Business Group Co., Ltd China Resources pharmaceutical business group has made great contributions to China Resources Pharmaceutical Group's successful entry into the top three There are five local subsidiaries of China Resources pharmaceutical business group, most of which are the source of inspection products Secondly, China Resources Shuanghe Pharmaceutical Co., Ltd was listed twice because of the disqualification of compound reserpine and lobeline hydrochloride injection China Resources Sanjiu (Linqing) Pharmaceutical Co., Ltd was listed once due to the disqualification of Cizhu pill At the same time, Bozhou Haomen Herbal Pieces Co., Ltd., ranking the third, is a local private enterprise mainly engaged in the management of herbal pieces and herbal medicines in Bozhou City, Anhui Province In May 2017, due to violation of the drug administration law of the people's Republic of China and the relevant provisions of GMP, the company was withdrawn the relevant GMP certificate by Anhui food and drug administration During the drug flight inspection issued by the State Food and drug administration, it was found that the company had some problems, such as incomplete sampling and inspection records, untrue inspection reports, suspected of fabricating batch production records, disordered material management, and nonstandard production site management Since 2017, the state has been strengthening the supervision of Chinese herbal pieces In 2017, the information notice of Chinese Herbal Pieces sampling accounted for 46.7% of the total number of notices, nearly half of which Chinese herbal medicine enterprises have almost become regular customers of "black list" With the acceleration of social aging, the demand of disease medication and medical care for the elderly is further increased As a kind of processed Chinese herbal medicine, Chinese herbal pieces can better store and protect the properties of Chinese herbal medicine, and the clinical medication is more convenient and safe In addition, the release of health care needs of the whole people, the deepening of the health concept, has given birth to the market capacity of Chinese herbal drinks In addition, the national policy guidance is conducive to the development of Chinese Herbal Pieces industry For example, the catalogue of foreign investment industry guidance explicitly prohibits foreign investment in "the application of traditional Chinese Herbal Pieces processing technology and the production of Chinese patent medicine secret recipe products", and prohibits the export of "Chinese Herbal Pieces processing technology" Secondly, under the medical reform policies of "cancel zero plus" and "reduce the proportion of drugs", Chinese herbal pieces are excluded The new version of the medical insurance catalogue strictly limits the use of traditional Chinese medicine injections, and indirectly benefits the development of traditional Chinese medicine pieces According to the 2017 Research Report on the development of Chinese Herbal Pieces industry, from 2006 to 2016, the average growth rate of Chinese Herbal Pieces reached 26.25%, and the whole industry grew In the first half of 2017, the revenue of four leading pharmaceutical enterprises of traditional Chinese medicine, namely, Kangmei pharmaceutical, China traditional Chinese medicine, Xiangxue pharmaceutical and Tailong pharmaceutical, increased by more than 10%, of which the revenue of traditional Chinese medicine business of Kangmei pharmaceutical increased by 35.81%, reaching 2.7 billion yuan However, on April 20 and December 15, 2017, Kangmei Pharmaceutical Co., Ltd was also named by the State Food and Drug Administration twice due to the disqualification of Chinese herbal pieces With the rapid growth of the industry, the disorder of the market of Chinese herbal pieces, such as shoddy, dyeing and weight gain, etc are frequently prominent Therefore, in order to ensure the drug safety of the people and promote the healthy development of Chinese Herbal Pieces industry, the State Food and drug administration has paid special attention to the quality supervision of Chinese Herbal Pieces in recent years Quality is becoming a key variable to influence the future development of the industry 2018 has come In the face of the major contradictions in the new era of China, I hope that when the pharmaceutical enterprises seize the future "cake", they are closer to people's demand for the continuous improvement of drug quality and far away from the "black list" of drugs Bozhou Chinese Herbal Pieces Market problems highlight the regional characteristics in the top 10 list of "black list" There are 4 Chinese Herbal Pieces enterprises in Bozhou When the reporter counted the data of the whole year, he was surprised to find that the enterprises of Chinese Herbal Pieces in Bozhou City, Anhui province had been listed 66 times in the "black list", involving 25 enterprises Bozhou City is one of the four pharmaceutical capitals in China, and it is the global distribution center and price formation center of traditional Chinese medicine At present, more than half of the top 100 pharmaceutical enterprises in China have settled in Bozhou, with 167 GMP certified pharmaceutical enterprises Bozhou's total production of Chinese Herbal Pieces accounts for 1 / 4 of the country In 2015, the annual trading volume of Chinese herbal materials has reached 22 billion yuan, accounting for about 1 / 5 of the country's market share However, under the bright appearance, Bozhou's traditional Chinese medicine market is full of fake and inferior products As early as 2012, the dyeing of Bozhou Herbal Pieces shocked the whole country In 2014, the food and Drug Administration of Anhui Province even found that some enterprises were suspected of leasing the drug production license The phenomenon of shoddy, dyeing and weight gain, illegal processing, adulteration and sale of fake products occurs from time to time Leaders of Anhui food and Drug Administration once said publicly that Bozhou's traditional Chinese medicine market has a long history of problems, and after each rectification, it will revive A small number of enterprises and individuals pursue economic benefits unilaterally and take risks, which makes illegal behaviors such as adulteration of Chinese herbal medicine and Chinese herbal pieces, increasing weight by dyeing and so on happen from time to time The reporter input "Bozhou" and "Chinese Herbal Pieces" in Tianyan search, and found 1106 results In 2012 or so, Bozhou's pharmaceutical companies were only about 300 Behind the numerous problems of Bozhou herbal pieces, it reflects the disorder of Bozhou traditional Chinese medicine industry, which is also the chronic disease of the whole industry In the future, the integration and merger of Chinese herbal pieces is the general trend Original title: Top 10 of "black list" of drugs of CFDA in 2017